1-5 of 5
Anja Engelke, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Low Incidence of Tumor Lysis Syndromes (TLS) and Infusion Related Reactions (IRR) in the CLL2-Bag Trial Evaluating a Sequential Treatment of Bendamustine (B), Obinutuzumab (GA101, G) and Venetoclax (ABT-199, A) in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Safety Results of a Phase-II-Trial of the German CLL Study Group (GCLLSG)

Paula Cramer, MD, Julia von Tresckow, MD, Jasmin Bahlo, PhD, Sandra Robrecht, Anja Engelke, MD, Petra Langerbeins, MD, Anna-Maria Fink, MD, Hyatt Balke-Want, MD, Othman Al-Sawaf, MD, Till Seiler, MD, Ludwig Fischer von Weikersthal, MD, Holger Hebart, MD, Kirsten Fischer, MD, Clemens-Martin Wendtner, MD, Stephan Stilgenbauer, Barbara F. Eichhorst, MD, Michael Hallek
Journal: Blood
Blood (2016) 128 (22): 2044.
https://doi.org/10.1182/blood.V128.22.2044.2044
Published: 2016
Journal Articles

CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial

Julia von Tresckow, MD, Paula Cramer, MD, Jasmin Bahlo, Sandra Robrecht, Anja Engelke, MD, Petra Langerbeins, MD, Anna-Maria Fink, MD, Thomas Illmer, MD, Holger Klaproth, MD, Sven Estenfelder, Matthias Ritgen, Kirsten Fischer, MD, Clemens-Martin Wendtner, MD, Karl-Anton Kreuzer, MD, Stephan Stilgenbauer, Sebastian Böttcher, Barbara Eichhorst, MD, Michael Hallek
Journal: Blood
Blood (2016) 128 (22): 640.
https://doi.org/10.1182/blood.V128.22.640.640
Published: 2016
Journal Articles

CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Results of a Phase II-Trial

Julia von Tresckow, MD, Paula Cramer, MD, Jasmin Bahlo, Anja Engelke, MD, Petra Langerbeins, MD, Anna-Maria Fink, MD, Holger Klaproth, MD, Eugen Tausch, MD, Kirsten Fischer, MD, Clemens-Martin Wendtner, MD, Karl-Anton Kreuzer, Stephan Stilgenbauer, MD, Sebastian Boettcher, Barbara Eichhorst, MD, Michael Hallek, MD
Journal: Blood
Blood (2015) 126 (23): 4151.
https://doi.org/10.1182/blood.V126.23.4151.4151
Published: 2015
Journal Articles

Salvage Therapy with Obinutuzumab (GA101) Plus Chlorambucil (Clb) after Treatment Failure of Clb Alone in Patients with Chronic Lymphocytic Leukemia (CLL) and Comorbidities: Results of the CLL11 Study

Valentin Goede, MD, Anja Engelke, MD, Kirsten Fischer, Javier Lopez Jimenez, Alexej Kuzmin, Martin JS Dyer, Katell Le Dû, Anna Marina Liberati, Rudolf Schlag, Anton W Langerak, Matthias Ritgen, Stephan Stilgenbauer, Elina Asikanius, Kathryn Humphrey, Michael K Wenger, Günter Fingerle-Rowson, Michael Hallek, MD
Journal: Blood
Blood (2014) 124 (21): 3327.
https://doi.org/10.1182/blood.V124.21.3327.3327
Published: 2014
Journal Articles

Risk Factors Associated with the Development of Infusion-Related Reactions in Patients with Chronic Lymphocytic Leukaemia Treated with Anti-CD20 Monoclonal Antibodies: Analysis of the CLL11 Study Dataset

Ciara Louise Freeman, MRCP, MD, Mark Dixon, Richard Houghton, Kathryn Humphrey, Gunter Fingerle-Rowson, MD PhD, Karl-Anton Kreuzer, MD, Anja Engelke, MD, Michael Hallek, MD, Valentin Goede, MD
Journal: Blood
Blood (2014) 124 (21): 3339.
https://doi.org/10.1182/blood.V124.21.3339.3339
Published: 2014